Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waiver under Section 712(c)(2)(B) and 18 U.S.C. §208(b)(3)

Ralph D'Agostino, I	Ph.D.			
Committees:	Nonprescription Drugs and the Pediatric Advisory Committees			
Meeting Date:	October 18-19, 2007			
I acknowledge that contingent upon public disclosure of the financial interest listed below, related to the safety and effectiveness of phenylephrine hydrochloride and phenylephrine bitartrate as Over-The-Counter (OTC) oral nasal decongestants, I am eligible to receive a waiver under Section 712(c)(2)(B) and 18 U.S.C. §208 (b)(3).				
Type of Interest		Nature		Magnitude
Unrelated Data Safety Monitor Board	ring	Affected firm		From \$10,001 to \$50,000 per year.
I hereby request that FDA make this information publicly available on my behalf at the start of the advisory committee meeting for which it is issued by reading the statement into the record at the time of the meeting. I understand that without public disclosure of this interest the waiver is not valid.				
/s/ Signature of SGE			10/11/07 Date	